Publisher
Springer International Publishing
Reference41 articles.
1. Chiesa C, Lassmann M. Dosimetry in nuclear medicine therapy. Q J Nucl Med Mol Imaging. 2011;55:2–4.
2. Wada N, Nakayama H, Suganuma N, Masudo Y, Rino Y, Masuda M, Imada T. Prognostic value of the sixth edition AJCC/UICC TNM classification for differentiated thyroid carcinoma with extrathyroid extension. J Clin Endocrinol Metab. 2007;92(1):215–8.
3. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.
4. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, Kvols LK, Krenning LP, Jamar F, Pauwels S. Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose–effect relationship. J Nucl Med. 2005;46:99S–106S.
5. Bergsma H, Konijnenberg M, van der Zwan WA, Kam BLR, Teunissen JJM, Kooij PP, Mauff KAL, Krenning EP, Kwekkeboom DJ. Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate. Eur J Nucl Med Mol Imaging. 2016;43(10):1802–11.